The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Impact of Body Mass Index on the Efficacy of Endocrine Therapy in Premenopausal Patients With Breast Cancer: An Analysis of the Prospective ABCSG-12 Trial
Open accessAbstract
Purpose: Aromatase inhibitors are effective as endocrine treatment for patients with hormone receptor–positive breast cancer. According to the hypothesis that overweight patients have higher levels of aromatase enzyme availability, we investigated the influence of body mass index (BMI) on the efficacy of adjuvant endocrine therapy in premenopausal patients in a retrospective analysis of the Austrian Breast and Colorectal Cancer Study Group (ABCSG) 12 trial. Patients and Methods: ABCSG-12 examined the efficacy of ovarian suppression using goserelin (3.6 mg subcutaneously every 28 days) in combination with anastrozole or tamoxifen with or without zoledronic acid (4 mg intravenously every 6 months) in premenopausal women with endocrine-responsive breast cancer. BMI was calculated using the prospectively collected data on patients' height and weight at study entry. BMI categories have been differentiated according to the WHO definition. Results: Overweight patients treated with anastrozole had a 60% increase in the risk of disease recurrence (hazard ratio [HR], 1.60; 95% CI, 1.06 to 2.41; P = .02) and more than a doubling in the risk of death (HR, 2.14; 95% CI, 1.17 to 3.92; P = .01) compared with normal weight patients treated with anastrozole. In the overweight group, patients treated with anastrozole had a nearly 50% increase in the risk of disease recurrence (HR, 1.49; 95% CI, 0.93 to 2.38; P = .08) and a three-fold increase in the risk of death (HR, 3.03; 95% CI, 1.35 to 6.82; P = .004) compared with patients treated with tamoxifen. Conclusion: BMI significantly impacts on the efficacy of anastrozole plus goserelin in premenopausal patients with breast cancer, probably through influencing aromatase availability and/or ovarian suppression by goserelin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase
Kato, S., Endoh, H., Masuhiro, Y., Kitamoto, T., Uchiyama, S., Sasaki, H., Masushige, S., Gotoh, Y., Nishida, E., Kawashima, H., et al. (1995) · Science · doi:10.1126/science.270.5241.1491 · Cited by 1,964
Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women
Endogenous Hormones Breast Cancer Collaborative Group (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djg022 · Cited by 1,093
Obesity, adipocytokines, and insulin resistance in breast cancer
Rose, D. P., Komninou, D., & Stephenson, G. D. (2004) · Obesity Reviews · doi:10.1111/j.1467-789x.2004.00142.x · Cited by 460
MacDonald, P. C., Edman, C. D., Hemsell, D. L., Porter, J. C., & Siiteri, P. K. (1978) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(78)90287-9 · Cited by 440
Cited by
Goldhirsch, A., Winer, E. P., Coates, A. S., Gelber, R. D., Piccart-Gebhart, M., Thürlimann, B., Senn, H.-J., Albain, K. S., André, F., Bergh, J., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt303 · Cited by 3,746
Self-citationObesity and Breast Cancer Prognosis: Evidence, Challenges, and Opportunities
Jiralerspong, S., & Goodwin, P. J. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.4480 · Cited by 405
The Impact of Obesity on Breast Cancer Diagnosis and Treatment
Lee, K., Kruper, L., Dieli-Conwright, C. M., & Mortimer, J. E. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0787-1 · Cited by 392
Gnant, M., Mlineritsch, B., Stoeger, H., Luschin-Ebengreuth, G., Knauer, M., Moik, M., Jakesz, R., Seifert, M., Taucher, S., Bjelic-Radisic, V., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdu544 · Cited by 312
Self-citationFranzoi, M. A., Agostinetto, E., Perachino, M., Del Mastro, L., de Azambuja, E., Vaz-Luis, I., Partridge, A. H., & Lambertini, M. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30666-5 · Cited by 290
Metadata
- Authors
- Pfeiler, G., Königsberg, R., Fesl, C., Mlineritsch, B., Stoeger, H., Singer, C. F., Pöstlberger, S., Steger, G. G., Seifert, M., Dubsky, P., Taucher, S., Samonigg, H., Bjelic-Radisic, V., Greil, R., Marth, C., & Gnant, M.
- Venue
- Journal of Clinical Oncology
- Published
- 2011-07-01
- Volume
- 29
- Issue
- 19
- Pages
- 2653-2659
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2116902655
- Cited by
- 221
- References
- 4
- FWCI
- 9.79
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Impact of Body Mass Index on the Efficacy of Endocrine Therapy in Premenopausal Patients With Breast Cancer: An Analysis of the Prospective ABCSG-12 Trial. https://app.cochat.ai/papers/10.1200/jco.2010.33.2585
- The paper
- Pfeiler, G., Königsberg, R., Fesl, C., Mlineritsch, B., Stoeger, H., Singer, C. F., Pöstlberger, S., Steger, G. G., Seifert, M., Dubsky, P., Taucher, S., Samonigg, H., Bjelic-Radisic, V., Greil, R., Marth, C., & Gnant, M. (2011). Impact of Body Mass Index on the Efficacy of Endocrine Therapy in Premenopausal Patients With Breast Cancer: An Analysis of the Prospective ABCSG-12 Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2010.33.2585
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.